Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Infliximab

Brand: Inflectra®, Remsima®
NICE TA: 383
Indication: Ankylosing spondylitis (NICE TA383)
Disease category: Musculoskeletal and joint diseases
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Infliximab is recommended, within its marketing authorisations, as an option for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red